MORRIS PLAINS, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as the Chairperson of the Audit Committee. Ms. Duncan has over 30 years of financial leadership experience, of which 17 are in the life sciences industry.

“We are honored to have Barbara join our Board. Barbara is an experienced Board director and a seasoned biotech executive with deep experience in corporate and financial strategy, and financial operations. Barbara will bring an extraordinary perspective to the Audit Committee, while overseeing financial discipline and enterprise risk management,” said Behzad Aghazadeh, Executive Chairman of Immunomedics.

Ms. Duncan previously served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. Prior to her leadership role with Intercept, Ms. Duncan was Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceutical Inc., which was sold to Euthymics Bioscience, Inc. in 2010.

“I am excited to join Immunomedics at this critical juncture as the Company is transitioning into a fully-integrated biopharmaceutical company,” said Ms. Duncan. “I look forward to working closely with the Board to unlock the full potential of sacituzumab govitecan for the benefit of patients.”

Ms. Duncan currently serves on the Board of Directors of Aevi Genomic Medicine, Inc., Adaptimmune Therapeutics, plc, Jounce Therapeutics, Inc., ObsEva SA, and OVID Therapeutics Inc. She received a M.B.A. from the Wharton School, University of Pennsylvania and a B.S. from Louisiana State University.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/.